API | eritoran

eritoran Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Eritoran is a synthetic lipid that inhibits the receptor TLR4. It was developed as a potential treatment for severe sepsis, an excessive inflammatory response to an infection. It failed a five year Phase III clinical trial, the results of which were published in 2013, and as of 2014 was no longer being developed. ^Wikipedia

Chemistry

SMILES: CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)(O)O)[C@@H]1OCC[C@@H](CCCCCCC)OC
InChIKey: BPSMYQFMCXXNPC-MFCPCZTFSA-N
Mol. Mass: 1313.68
ALogP: Missing data
ChEMBL Molecules:

eritoran

eritoran tetrasodium

eritoran

eritoran tetrasodium

More Chemistry

Pharmacology

Mechanism of Action:
- Lymphocyte antigen 96 (Homo sapiens) ^UniProt
- Toll-like receptor 4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Infections (Phase 2)

Insulin Resistance (Phase 2)

Leukemia (Phase 1)

Sepsis (Phase 3)

Shock, Septic (Phase 2)

Systemic Inflammatory Response Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue